Population
Tumor microenvironment and T cells
Design
Preclinical
Authors
Loading...
Kynureninase merits clinical trial evaluation as selective immunotherapy; extends tryptophan pathway targeting beyond IDO inhibition.
Kynureninase is proposed as a strategy to degrade kynurenine in the tumor microenvironment, aiming to restore anti-tumor immunity without harming healthy cell tryptophan metabolism.
Wikstrand et al. (1978) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: